Gemtesa Now Available for Overactive Bladder Treatment
Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist.
Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist.
Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more.
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.
Researchers conducted meta-analyses to investigate the real rates of persistence and adherence to overactive bladder drug therapies and moderating factors.
The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.
The approval was based on data from the pivotal phase 3 EMPOWUR study.
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
Pharmacologic therapy may improve symptoms in patients with refractory overactive bladder who receive intravesical onabotulinum toxin-A injections.